Previous 10 | Next 10 |
2024-03-19 10:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-13 16:42:19 ET More on Solid Biosciences Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid Solid Biosciences reports Q4 results Solid Biosciences signs agreement with Armatus Bio for AAV-SLB101 Seeking Alpha’s Quant Ratin...
2024-03-13 13:46:03 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2023 Earnings Call Transcript Biotech And Pharma Diversification Pays Off Catalyst Pharmaceuticals At A Crossroads: Firdapse Litigation And Agamree's Launch Catal...
2024-03-13 08:00:00 ET Sarepta Therapeutics (NASDAQ: SRPT) could have a serious new competitor on the horizon. According to some fresh clinical data from Regenxbio (NASDAQ: RGNX) , another biotech, the company is making headway with a gene therapy for Duchenne muscular dystr...
2024-03-11 11:53:40 ET Summary Positive interim results released from phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. Functional and strength data from the phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients...
2024-03-08 09:23:14 ET More on Regenxbio REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips Regenxbio stock jumps 13% on positive data for DMD drug Regenxbio Q4 2023 Earnings Preview...
2024-03-05 11:03:07 ET More on Regenxbio REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips Regenxbio Q4 2023 Earnings Preview Regenxbio spikes after trial win for gene therapy in Hu...
2024-03-04 09:47:00 ET On Feb. 20, Wedbush financial analyst Andreas Argyrides restated his price target for Sarepta Therapeutics (NASDAQ: SRPT) stock, claiming that its shares would reach $224, rising 73% in the process. Argyrides' calculation is likely that Sarepta will successful...
– Applications for the 2024-2025 academic year will be accepted until May 13, 2024 – Scholarships will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals living with Duchenne Sarepta T...
2024-02-29 00:00:16 ET Image source: The Motley Fool. Sarepta Therapeutics (NASDAQ: SRPT) Q4 2023 Earnings Call Feb 28, 2024 , 4:30 p.m. ET Operator Continue reading For further details see: Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Tr...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
– TIME recognizes Dr. Mendell’s decades-long contributions in the treatment of neuromuscular disease and the advancement of gene therapy, including the first gene therapy for Duchenne muscular dystrophy Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precisio...
With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows: Wall Street...
2024-05-01 19:30:13 ET Image source: The Motley Fool. Sarepta Therapeutics (NASDAQ: SRPT) Q1 2024 Earnings Call May 01, 2024 , 4:30 p.m. ET Operator Continue reading For further details see: Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Tr...